3ce5
From Proteopedia
(Difference between revisions)
m (Protected "3ce5" [edit=sysop:move=sysop]) |
|||
Line 1: | Line 1: | ||
- | [[ | + | ==A bimolecular parallel-stranded human telomeric quadruplex in complex with a 3,6,9-trisubstituted acridine molecule BRACO19== |
+ | <StructureSection load='3ce5' size='340' side='right' caption='[[3ce5]], [[Resolution|resolution]] 2.50Å' scene=''> | ||
+ | == Structural highlights == | ||
+ | <table><tr><td colspan='2'>[[3ce5]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3CE5 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3CE5 FirstGlance]. <br> | ||
+ | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BRA:9-[4-(N,N-DIMETHYLAMINO)PHENYLAMINO]-3,6-BIS(3-PYRROLIDINOPROPIONAMIDO)+ACRIDINE'>BRA</scene>, <scene name='pdbligand=K:POTASSIUM+ION'>K</scene></td></tr> | ||
+ | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1k8p|1k8p]]</td></tr> | ||
+ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3ce5 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3ce5 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3ce5 RCSB], [http://www.ebi.ac.uk/pdbsum/3ce5 PDBsum]</span></td></tr> | ||
+ | </table> | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | The crystal structure of a complex between the bimolecular human telomeric quadruplex d(TAGGGTTAGGGT)2 and the experimental anticancer drug BRACO-19, has been determined, to 2.5 A resolution. The binding site for the BRACO-19 molecule is at the interface of two parallel-folded quadruplexes, sandwiched between a G-tetrad surface and a TATA tetrad, and held in the site by networks of water molecules. The structure rationalizes the existing structure-activity data and provides a starting-point for the structure-based design of quadruplex-binding ligands | ||
- | + | Structural basis of DNA quadruplex recognition by an acridine drug.,Campbell NH, Parkinson GN, Reszka AP, Neidle S J Am Chem Soc. 2008 May 28;130(21):6722-4. Epub 2008 May 6. PMID:18457389<ref>PMID:18457389</ref> | |
- | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
- | + | </div> | |
- | + | == References == | |
- | + | <references/> | |
- | + | __TOC__ | |
- | + | </StructureSection> | |
- | + | ||
- | == | + | |
- | < | + | |
[[Category: Campbell, N H.]] | [[Category: Campbell, N H.]] | ||
[[Category: Neidle, S.]] | [[Category: Neidle, S.]] |
Revision as of 09:33, 5 November 2014
A bimolecular parallel-stranded human telomeric quadruplex in complex with a 3,6,9-trisubstituted acridine molecule BRACO19
|
Categories: Campbell, N H. | Neidle, S. | Parkinson, G N. | Reszka, A P. | Acridine | Bimolecular | Braco19 | Complex | Dna | Human | Parallel | Quadruplex | Telomere | Trisubstituted